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Short interfering RNA (siRNA) is an effective mediator of
RNA interference[1] and holds great promise as a ther-
apeutic agent.[1,2] However, the therapeutic potency of
siRNA is severely limited by delivery problems.[2–5]
PEGylation, a technique commonly used to improve the
in vivo pharmacokinetics of protein therapeutics,[6,7] has
also been investigated for siRNA delivery.[8–16] Covalent
conjugation of a PEG chain to siRNA has shown to increase
serum stability of siRNA with sufficient gene silencing
efficiency.[10,11] Similar to the most of the protein PEGyla-
tion studies, all PEGylation strategies for siRNA delivery
have been limited to the use of linear PEG,[8–15] and in one
case, six-arm PEG.[16]
Protein PEGylation studies have revealed that branched
PEG can be more effective in enhancing the biological half-library.com DOI: 10.1002/marc.201000804
Scheme 1. Conjugation of thiol-modified siRNA with RAFT-synthesized pyridyldisulfide
functionalized p(PEGA).
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enhanced resistance against proteolysis
and reduced immunogenicity due to its
umbrella-like shape.[6,17,18] Recently,
comb-like PEG polymers, i.e., polyethy-
lene glycol grafted poly(meth)acrylates,
have proved to be potent alternatives to
linear and branched PEG for improving
the pharmacokinetics of protein
drugs.[18–20] When compared to the
linear PEG with equivalent molecular
weights, the comb-like PEG displays
greater steric hindrance, thus potentiallyenhancing biostability and lowering clearance rates of the
conjugated biotherapeutics. Moreover, comb-shaped PEG-
(meth)acrylate polymers can be prepared by reversible
addition fragmentation chain transfer (RAFT) polymeriza-
tion[21–25] and atom transfer radical polymerization (ATRP)
techniques,[26–29] which offer facile synthetic routes to the
generation of polymers with controlled molecular weight,
varying macromolecular architectures and defined end-
group functionalities. While control over the molecular
weight and macromolecular structure of the conjugated
polymer is crucial for improved pharmacokinetic properties
of the bioconjugates, the defined end-group functionality
enables varying synthetic strategies to be implemented for
site-specific PEGylation.
Recently, we demonstrated the straightforward synth-
esis of reversible, well-defined siRNA-poly(polyethylene
glycol methyl ether acrylate) (p(PEGA)) conjugates via the
RAFT polymerization technique.[30] In the present study, we
have investigated, for the first time, the in vitro serum
stability and gene silencing activity of the siRNA-p(PEGA)
conjugates. Briefly, a 50-sense-thiol-modified siRNA target-
ing the enhanced green fluorescence protein (eGFP) gene
was conjugated covalently with two different p(PEGA)
polymers having different molecular weights via a
reversible disulphide linkage. The serum and nuclease
stability, cytotoxicity and gene silencing activity of the low
and high molecular weight conjugates (LMWC and HMWC,
respectively) were investigated. The results are summar-
ized below.Experimental Part
Materials and methods are given in Supporting Information.Results and Discussion
Pyridyldisulfide-terminated poly(PEG-acrylate) (p(PEGA))
synthesized by RAFT polymerization using a pyridyldisul-
fide-modified RAFT agent (Figure S1 and S2, Supportingwww.MaterialsViews.com
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siRNA[30] that targets the gene expressing enhanced green
fluorescence protein (eGFP) (Scheme 1). The conjugation of
siRNA with the polymers (low molecular weight polymer
(LMWP)¼ 6 000 gmol1, polydispersity index or PDI¼ 1.10
and high molecular weight polymer (HMWP)¼ 17 400
gmol1, PDI¼ 1.19) was evident in gel electrophoresis data
by the shift of the bands (as a smear) to higher molecular
weights compared to the free siRNA (Figure 1A). The higher
molecular weight band in the unconjugated siRNA lane
(Lane 1) was attributed to the disulphide-linked dimers of
siRNA. The average conjugation yield calculated by measur-
ing the intensity of the bands in Figure 1A using ImageJ
software was 68 3% and 69 3% for low and high
molecular weight conjugates (LMWC and HMWC), respec-
tively.
The conjugation of p(PEGA) to siRNA through a disulfide
linkage should enable the release of siRNA from the
polymer chain under reductive conditions such as those
present within the cells.[31] Both low and high molecular
weight conjugates (LMWC and HMWC, respectively) were
treated with glutathione at intracellular concentrations
(10 mM) for 1 h. The gel electrophoresis results (Figure 1B
and C) showed that both conjugates were cleaved
completely after treatment with glutathione.
The stability of the unmodified siRNA and its conjugates
was tested in 80% active fetal bovine serum (FBS) (Figure
S3–S6, Supporting information). The unmodified siRNA and
thiol-modified siRNA were completely degraded within 10
and 48 h, respectively (Figure 2A). The degradation of LMWC
and HMWC was much slower. The band intensity of the
conjugates did not show a profound change within 48 h. At
72 h, the HMWC degradation was only 16%. A previous
study[32] showed that the siRNA-linear PEG (Mn 5 000)
conjugates had higher stability in 50% fetal bovine serum
compared to the naked siRNA; however, these conjugates
completely degraded in 50% serum within 24 h. The higher
stability of the siRNA conjugates with PEG-based polymers
can be attributed to the steric hindrance effect of the
polymer preventing the interactions between siRNA and
the nucleases. Although not directly comparable, the higher. 2011, 32, 654–659
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Figure 1. Polyacrylamide gel electrophoresis of (A) conjugation reactionmixtures, (B) and (C) siRNA-polymer conjugates (B-HMWC; C-LMWC)
before and after reaction with 10mM glutathione (GSH), (D) siRNA-polymer conjugates after HPLC purification and subsequent dialysis. (A)
Lane 1 – unconjugated siRNA; Lanes 2 and 3 – LMWC and HMWC conjugation mixtures, respectively; M – 10 bp DNA marker. (B) Lane 1 –
unconjugated siRNA; Lanes 2 and 3 – HMWC before and after treatment with GSH, respectively; M – 36 bp DNA marker. (C) Lane 1 –
unconjugated siRNA; Lanes 2 and 3 – LMWC before and after treatment with GSH, respectively; M – Trackit 100 bp DNAmarker. (D) Lane 1 –
unconjugated siRNA (containing disulfide crosslinked dimer); Lane 2 – unconjugated siRNA after treatment with 200mM dithioerihtriol for
2 h (avoiding disulfide crosslinked dimer); Lanes 3 and 4 – purified LMWC and HMWC, respectively; Lane 5 – 10 bp DNA marker. All samples
contained 0.03 nmol siRNA.
Figure 2. (A) Degradation of unmodified siRNA, thiol-modified siRNA, LMWC and HMWC in 80% active FBS, derived from PAGE data (Figure
S3–S6, SI), as described in SI. The results are the average of three independent experiments standard deviation. (B) Nuclease stability
assay: Lane 1: Marker Lanes 2 and 4 – LMWC before and after incubation with nuclease for 60min, respectively; Lanes 3 and 5 – HMWC
before and after incubation with nuclease for 60min, respectively; Lanes 6 and 7 – unconjugated (thiol-modified) siRNA before and after
incubation with nuclease for 60min, respectively.
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K. Gunasekaran, T. H. Nguyen, H. D. Maynard, T. P. Davis, V. Bulmusserum stability of siRNA-p(PEGA) conjugates relative to
siRNA-linear PEG conjugates can be attributed to the
umbrella-like shape of p(PEGA), potentially providing
greater protection to siRNA.
The stability of the conjugates was also tested against
RNase ONETM ribonuclease, a periplasmic enzyme that
catalyzes the degradation of RNA by cleaving the phos-
phodiester bond between any two ribonucleotides. The
unconjugated thiol-modified siRNA was completelyMacromol. Rapid Commun
 2011 WILEY-VCH Verlag Gmbdegraded in 60 min (Figure 2B, Lane 6). The LMWC band
mostly disappeared after 60 min (Lane 4). Interestingly,
HMWC remained mostly stable within 60 min. A control
experiment that was performed to investigate the inhibi-
tory effect of the p(PEGA), if there was any, on the
ribonuclease activity showed that the unconjugated
(thiol-modified) siRNA when simply mixed with the
polymer (HMWP) (at a 1:1 molar ratio) resulted in complete
degradation of the siRNA in 30 min after the incubation. 2011, 32, 654–659
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stability of the HMWC can be attributed to the greater steric
hindrance of the higher molecular weight polymer chain
relative to the lower molecular weight polymer.
Before proceeding to the cell culture experiments, semi-
preparative HPLC was performed to remove the unconju-
gated siRNA present in the conjugate mixtures. The PAGE
analysis of the purified conjugates (Figure 1D) showed
clearly that the free RNA band, previously present in the
conjugate reaction mixtures in Figure 1A, was absent after
the HPLC process.
The conjugates (LMWC and HMWC) were then formu-
lated with a well-known fusogenic peptide KALA,[33] (at an
(þ/–) ratio of 2) to investigate the gene silencing ability of
the conjugates. KALA has proved to enable the endoplasmic
escape of oligonucleotides. It has been previously demon-
strated that KALA and oligonucleotides form complexes
between 1.25 and 2.5 (þ/–) charge ratio and the (þ/–) ratio
required to provide an efficient transfection is usually 10.[33]
The formation of KALA complexes with siRNA-p(PEGA)
conjugates was verified by PAGE (Figure S8, ESI).
Human neuroblastoma (SH-EP) cells were used as a
model cell line in both cytotoxicity and gene silencing
experiments. Considering the potential of polymer-based
therapeutics in tumor treatments, SH-EP cell line was
chosen as a suitable model for testing the polymer
conjugates. A cell viability assay showed that lipofectamine
alone caused the lowest cell viability (80%). None of the
other samples caused significant inhibition on the cell
viability (>85%) at the concentrations tested (Figure 3).Figure 3. Viability of SH-EP cells incubated with unmodified siRNA
(n-siRNA), transfection agents (lipofectamine and KALA), n-siRNA
complexes with KALA (n-siRNA-K, (þ/–)¼ 2) or lipofectamine (n-
siRNA-L), the conjugates (LMWC and HMWC), LMWC or HMWC
complex with KALA (LMWC-K, HMWC-K, respectively (þ/–)¼ 2)
for 72 h. The concentration of the samples was equivalent to
50 nM siRNA. The negative and positive controls are the cells with
no treatment and treated with Triton X-100 (2 wt.-%), respect-
ively. The results are the average of three independent experi-
ments standard error.
www.MaterialsViews.com
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tested on SH-EP cells stably expressing eGFP (after 72 h post-
transfection with the samples equivalent to 50 nM siRNA
concentration). The fluorescence microscopy (Figure 4)
showed that eGFP expression was not affected by the
treatments with n-siRNA or n-siRNA-KALA complex.
Contrary, siRNA-lipofectamine complex (siRNA-L) strongly
reduced the fluorescence. Interestingly, the activity of the
KALA complexes of both conjugates ((þ/–)¼ 2) on the eGFP
expression was comparable with the activity of siRNA-L.
The eGFP expression was also quantitatively investigated
using flow cytometry (Figure 4, top graph). The KALA
complex of the unmodified siRNA caused only 2 8%
protein inhibition while the KALA complexes of LMWC and
HMWC showed 56 5% and 58 3% eGFP inhibition,
respectively. The protein inhibition caused by the KALA
complexes of the LMWC and HMWC was comparable to the
effect of the siRNA-lipofectamine complex (77 7%). The
flow cytometry results further revealed that the conjugates
alone (both LMWC and HMWC) without a transfection
agent inhibited the eGFP expression by 28 1% and
29 5%, respectively, while the inhibition of the unmodi-
fied siRNA without a transfection agent was only 9 7%.
The combination of the protein inhibition and serum
stability results suggest that the enhanced serum stability
of the siRNA conjugated with p(PEGA)s might result in the
enhanced protein inhibition.Conclusion
In this study, we demonstrated, for the first time, the effects
of the RAFT-synthesized comb-type PEG conjugation on
siRNA’s in vitro stability and gene inhibition activity. The
results support the comb-like PEG (meth)acrylate polymers
synthesized by RAFT polymerization as an effective
component of delivery systems for siRNA. Since RAFT
polymerization is versatile, one can envision preparing
copolymers containing complexation and endosomal
release functionality for siRNA delivery.Acknowledgements: The authors acknowledge the Australian
Research Council (ARC) for funding (DP 0770818). T.P.D. acknowl-
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Figure 4. The eGFP inhibition (%) results obtained by flow cytometry and representative epi-fluorescence micrographs of SH-EP cells at 72 h
post-transfection without any treatment (negative), and with unmodified (n-siRNA), its complexes with KALA (n-siRNA-K, (þ/ )¼ 2) and
lipofectamine (n-siRNA-L), and with LMWC, LMWC complex with KALA (LMWC-K, (þ/ )¼ 2), and HMWC and HMWC complex with KALA
(HMWC-K, (þ/ )¼ 2). The concentration of the samples was equivalent to 50 nM siRNA. In the upper graph, neg-RNA, and neg-siRNA-K and
neg-siRNA-L are negative control siRNA and its complexes with KALA and lipofectamine, respectively. The results are the average of three
different experiments standard error.
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